Loading…
Cetuximab‐associated pulmonary toxicity in concurrent chemoradiation for the treatment of a squamous cell carcinoma of the head and neck
Background Cetuximab is a common EGFR monoclonal antibody used with radiotherapy to treat head‐and‐neck cancer. Severe pulmonary toxicity, including interstitial lung disease (ILD), caused by cetuximab is rare. Methods We describe a patient who developed ILD and acute respiratory failure after concu...
Saved in:
| Published in: | Head & neck 2019-04, Vol.41 (4), p.E55-E58 |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4198-78744f56c36d19779a7647154859e3e43a43e0bd896e3be7236fb4a07c9e5ed43 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4198-78744f56c36d19779a7647154859e3e43a43e0bd896e3be7236fb4a07c9e5ed43 |
| container_end_page | E58 |
| container_issue | 4 |
| container_start_page | E55 |
| container_title | Head & neck |
| container_volume | 41 |
| creator | Mayfield, John D. Mercado, Catherine E. Kaye, Frederic J. Mendenhall, William M. |
| description | Background
Cetuximab is a common EGFR monoclonal antibody used with radiotherapy to treat head‐and‐neck cancer. Severe pulmonary toxicity, including interstitial lung disease (ILD), caused by cetuximab is rare.
Methods
We describe a patient who developed ILD and acute respiratory failure after concurrent chemoradiation with cetuximab for oropharyngeal squamous cell carcinoma, and review the literature.
Results
A patient developed acute respiratory failure 2 months after starting concurrent chemoradiation with cetuximab and was hospitalized in intensive care after a procedure for progressive respiratory distress. Cultures and serology were negative for infection and radiologic findings were consistent with drug associated pneumonitits. Steroids were administered until the patient was stabilized. The patient fully recovered 1 month after the onset of respiratory distress, although he died of recurrent disease 10 months after completing treatment.
Conclusion
Although severe pulmonary toxicity caused by EGFR inhibitors has been well described in the literature, ILD caused by cetuximab, an EGFR monoclonal antibody, is rare and not well‐documented. Given its life‐threatening effects, awareness of this potential side effect and early diagnosis is critical. |
| doi_str_mv | 10.1002/hed.25528 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2191357949</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2191357949</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4198-78744f56c36d19779a7647154859e3e43a43e0bd896e3be7236fb4a07c9e5ed43</originalsourceid><addsrcrecordid>eNp1kLtOwzAUQC0EouUx8APIEhNDih07cTyiUh5SJRaYI8e5UQOJ3dqOaDdmJr6RLyGh7cjkK9-jc6WD0AUlE0pIfLOAchInSZwdoDElUkSEcXE4zJxFjAg-QifevxFCWMrjYzRiJKWcxskYfU0hdOu6VcXP57fy3upaBSjxsmtaa5Tb4GDXta7DBtcGa2t05xyYgPUCWutU2eO1NbiyDocF4OBAhXYAbIUV9qtOtbbzWEPTYK2cro1t1bAc6AWoEitTYgP6_QwdVarxcL57T9Hr_exl-hjNnx-eprfzSHMqs0hkgvMqSTVLSyqFkEqkXNCEZ4kEBpwpzoAUZSZTYAWImKVVwRURWkICJWen6GrrXTq76sCH_M12zvQn85hKyhIhueyp6y2lnfXeQZUvXZ_JbXJK8qF63lfP_6r37OXO2BVt_7sn95l74GYLfNQNbP435Y-zu63yF5DQjkg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2191357949</pqid></control><display><type>article</type><title>Cetuximab‐associated pulmonary toxicity in concurrent chemoradiation for the treatment of a squamous cell carcinoma of the head and neck</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Mayfield, John D. ; Mercado, Catherine E. ; Kaye, Frederic J. ; Mendenhall, William M.</creator><creatorcontrib>Mayfield, John D. ; Mercado, Catherine E. ; Kaye, Frederic J. ; Mendenhall, William M.</creatorcontrib><description>Background
Cetuximab is a common EGFR monoclonal antibody used with radiotherapy to treat head‐and‐neck cancer. Severe pulmonary toxicity, including interstitial lung disease (ILD), caused by cetuximab is rare.
Methods
We describe a patient who developed ILD and acute respiratory failure after concurrent chemoradiation with cetuximab for oropharyngeal squamous cell carcinoma, and review the literature.
Results
A patient developed acute respiratory failure 2 months after starting concurrent chemoradiation with cetuximab and was hospitalized in intensive care after a procedure for progressive respiratory distress. Cultures and serology were negative for infection and radiologic findings were consistent with drug associated pneumonitits. Steroids were administered until the patient was stabilized. The patient fully recovered 1 month after the onset of respiratory distress, although he died of recurrent disease 10 months after completing treatment.
Conclusion
Although severe pulmonary toxicity caused by EGFR inhibitors has been well described in the literature, ILD caused by cetuximab, an EGFR monoclonal antibody, is rare and not well‐documented. Given its life‐threatening effects, awareness of this potential side effect and early diagnosis is critical.</description><identifier>ISSN: 1043-3074</identifier><identifier>EISSN: 1097-0347</identifier><identifier>DOI: 10.1002/hed.25528</identifier><identifier>PMID: 30614125</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>cetuximab ; chemoradiation ; Chemoradiotherapy ; Epidermal growth factor receptors ; Head & neck cancer ; Head and neck ; head and neck cancer ; Immunotherapy ; Lung cancer ; Lung diseases ; Monoclonal antibodies ; Neck ; oropharynx ; Patients ; pulmonary toxicity ; Radiation therapy ; Respiratory failure ; Respiratory therapy ; Serology ; Squamous cell carcinoma ; Steroid hormones ; Targeted cancer therapy ; Toxicity</subject><ispartof>Head & neck, 2019-04, Vol.41 (4), p.E55-E58</ispartof><rights>2019 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4198-78744f56c36d19779a7647154859e3e43a43e0bd896e3be7236fb4a07c9e5ed43</citedby><cites>FETCH-LOGICAL-c4198-78744f56c36d19779a7647154859e3e43a43e0bd896e3be7236fb4a07c9e5ed43</cites><orcidid>0000-0002-6592-2810</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30614125$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mayfield, John D.</creatorcontrib><creatorcontrib>Mercado, Catherine E.</creatorcontrib><creatorcontrib>Kaye, Frederic J.</creatorcontrib><creatorcontrib>Mendenhall, William M.</creatorcontrib><title>Cetuximab‐associated pulmonary toxicity in concurrent chemoradiation for the treatment of a squamous cell carcinoma of the head and neck</title><title>Head & neck</title><addtitle>Head Neck</addtitle><description>Background
Cetuximab is a common EGFR monoclonal antibody used with radiotherapy to treat head‐and‐neck cancer. Severe pulmonary toxicity, including interstitial lung disease (ILD), caused by cetuximab is rare.
Methods
We describe a patient who developed ILD and acute respiratory failure after concurrent chemoradiation with cetuximab for oropharyngeal squamous cell carcinoma, and review the literature.
Results
A patient developed acute respiratory failure 2 months after starting concurrent chemoradiation with cetuximab and was hospitalized in intensive care after a procedure for progressive respiratory distress. Cultures and serology were negative for infection and radiologic findings were consistent with drug associated pneumonitits. Steroids were administered until the patient was stabilized. The patient fully recovered 1 month after the onset of respiratory distress, although he died of recurrent disease 10 months after completing treatment.
Conclusion
Although severe pulmonary toxicity caused by EGFR inhibitors has been well described in the literature, ILD caused by cetuximab, an EGFR monoclonal antibody, is rare and not well‐documented. Given its life‐threatening effects, awareness of this potential side effect and early diagnosis is critical.</description><subject>cetuximab</subject><subject>chemoradiation</subject><subject>Chemoradiotherapy</subject><subject>Epidermal growth factor receptors</subject><subject>Head & neck cancer</subject><subject>Head and neck</subject><subject>head and neck cancer</subject><subject>Immunotherapy</subject><subject>Lung cancer</subject><subject>Lung diseases</subject><subject>Monoclonal antibodies</subject><subject>Neck</subject><subject>oropharynx</subject><subject>Patients</subject><subject>pulmonary toxicity</subject><subject>Radiation therapy</subject><subject>Respiratory failure</subject><subject>Respiratory therapy</subject><subject>Serology</subject><subject>Squamous cell carcinoma</subject><subject>Steroid hormones</subject><subject>Targeted cancer therapy</subject><subject>Toxicity</subject><issn>1043-3074</issn><issn>1097-0347</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp1kLtOwzAUQC0EouUx8APIEhNDih07cTyiUh5SJRaYI8e5UQOJ3dqOaDdmJr6RLyGh7cjkK9-jc6WD0AUlE0pIfLOAchInSZwdoDElUkSEcXE4zJxFjAg-QifevxFCWMrjYzRiJKWcxskYfU0hdOu6VcXP57fy3upaBSjxsmtaa5Tb4GDXta7DBtcGa2t05xyYgPUCWutU2eO1NbiyDocF4OBAhXYAbIUV9qtOtbbzWEPTYK2cro1t1bAc6AWoEitTYgP6_QwdVarxcL57T9Hr_exl-hjNnx-eprfzSHMqs0hkgvMqSTVLSyqFkEqkXNCEZ4kEBpwpzoAUZSZTYAWImKVVwRURWkICJWen6GrrXTq76sCH_M12zvQn85hKyhIhueyp6y2lnfXeQZUvXZ_JbXJK8qF63lfP_6r37OXO2BVt_7sn95l74GYLfNQNbP435Y-zu63yF5DQjkg</recordid><startdate>201904</startdate><enddate>201904</enddate><creator>Mayfield, John D.</creator><creator>Mercado, Catherine E.</creator><creator>Kaye, Frederic J.</creator><creator>Mendenhall, William M.</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><orcidid>https://orcid.org/0000-0002-6592-2810</orcidid></search><sort><creationdate>201904</creationdate><title>Cetuximab‐associated pulmonary toxicity in concurrent chemoradiation for the treatment of a squamous cell carcinoma of the head and neck</title><author>Mayfield, John D. ; Mercado, Catherine E. ; Kaye, Frederic J. ; Mendenhall, William M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4198-78744f56c36d19779a7647154859e3e43a43e0bd896e3be7236fb4a07c9e5ed43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>cetuximab</topic><topic>chemoradiation</topic><topic>Chemoradiotherapy</topic><topic>Epidermal growth factor receptors</topic><topic>Head & neck cancer</topic><topic>Head and neck</topic><topic>head and neck cancer</topic><topic>Immunotherapy</topic><topic>Lung cancer</topic><topic>Lung diseases</topic><topic>Monoclonal antibodies</topic><topic>Neck</topic><topic>oropharynx</topic><topic>Patients</topic><topic>pulmonary toxicity</topic><topic>Radiation therapy</topic><topic>Respiratory failure</topic><topic>Respiratory therapy</topic><topic>Serology</topic><topic>Squamous cell carcinoma</topic><topic>Steroid hormones</topic><topic>Targeted cancer therapy</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mayfield, John D.</creatorcontrib><creatorcontrib>Mercado, Catherine E.</creatorcontrib><creatorcontrib>Kaye, Frederic J.</creatorcontrib><creatorcontrib>Mendenhall, William M.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Head & neck</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mayfield, John D.</au><au>Mercado, Catherine E.</au><au>Kaye, Frederic J.</au><au>Mendenhall, William M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cetuximab‐associated pulmonary toxicity in concurrent chemoradiation for the treatment of a squamous cell carcinoma of the head and neck</atitle><jtitle>Head & neck</jtitle><addtitle>Head Neck</addtitle><date>2019-04</date><risdate>2019</risdate><volume>41</volume><issue>4</issue><spage>E55</spage><epage>E58</epage><pages>E55-E58</pages><issn>1043-3074</issn><eissn>1097-0347</eissn><abstract>Background
Cetuximab is a common EGFR monoclonal antibody used with radiotherapy to treat head‐and‐neck cancer. Severe pulmonary toxicity, including interstitial lung disease (ILD), caused by cetuximab is rare.
Methods
We describe a patient who developed ILD and acute respiratory failure after concurrent chemoradiation with cetuximab for oropharyngeal squamous cell carcinoma, and review the literature.
Results
A patient developed acute respiratory failure 2 months after starting concurrent chemoradiation with cetuximab and was hospitalized in intensive care after a procedure for progressive respiratory distress. Cultures and serology were negative for infection and radiologic findings were consistent with drug associated pneumonitits. Steroids were administered until the patient was stabilized. The patient fully recovered 1 month after the onset of respiratory distress, although he died of recurrent disease 10 months after completing treatment.
Conclusion
Although severe pulmonary toxicity caused by EGFR inhibitors has been well described in the literature, ILD caused by cetuximab, an EGFR monoclonal antibody, is rare and not well‐documented. Given its life‐threatening effects, awareness of this potential side effect and early diagnosis is critical.</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>30614125</pmid><doi>10.1002/hed.25528</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-6592-2810</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1043-3074 |
| ispartof | Head & neck, 2019-04, Vol.41 (4), p.E55-E58 |
| issn | 1043-3074 1097-0347 |
| language | eng |
| recordid | cdi_proquest_journals_2191357949 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | cetuximab chemoradiation Chemoradiotherapy Epidermal growth factor receptors Head & neck cancer Head and neck head and neck cancer Immunotherapy Lung cancer Lung diseases Monoclonal antibodies Neck oropharynx Patients pulmonary toxicity Radiation therapy Respiratory failure Respiratory therapy Serology Squamous cell carcinoma Steroid hormones Targeted cancer therapy Toxicity |
| title | Cetuximab‐associated pulmonary toxicity in concurrent chemoradiation for the treatment of a squamous cell carcinoma of the head and neck |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T22%3A15%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cetuximab%E2%80%90associated%20pulmonary%20toxicity%20in%20concurrent%20chemoradiation%20for%20the%20treatment%20of%20a%20squamous%20cell%20carcinoma%20of%20the%20head%20and%20neck&rft.jtitle=Head%20&%20neck&rft.au=Mayfield,%20John%20D.&rft.date=2019-04&rft.volume=41&rft.issue=4&rft.spage=E55&rft.epage=E58&rft.pages=E55-E58&rft.issn=1043-3074&rft.eissn=1097-0347&rft_id=info:doi/10.1002/hed.25528&rft_dat=%3Cproquest_cross%3E2191357949%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4198-78744f56c36d19779a7647154859e3e43a43e0bd896e3be7236fb4a07c9e5ed43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2191357949&rft_id=info:pmid/30614125&rfr_iscdi=true |